Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Cash & Current Investments (2019 - 2025)

Historic Cash & Current Investments for Harmony Biosciences Holdings (HRMY) over the last 7 years, with Q3 2025 value amounting to $672.6 million.

  • Harmony Biosciences Holdings' Cash & Current Investments rose 5397.07% to $672.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $672.6 million, marking a year-over-year increase of 5397.07%. This contributed to the annual value of $467.2 million for FY2024, which is 1669.79% up from last year.
  • According to the latest figures from Q3 2025, Harmony Biosciences Holdings' Cash & Current Investments is $672.6 million, which was up 5397.07% from $565.3 million recorded in Q2 2025.
  • In the past 5 years, Harmony Biosciences Holdings' Cash & Current Investments ranged from a high of $672.6 million in Q3 2025 and a low of $141.2 million during Q1 2021
  • Its 5-year average for Cash & Current Investments is $362.4 million, with a median of $370.7 million in 2023.
  • As far as peak fluctuations go, Harmony Biosciences Holdings' Cash & Current Investments plummeted by 1444.76% in 2021, and later skyrocketed by 6223.33% in 2022.
  • Quarter analysis of 5 years shows Harmony Biosciences Holdings' Cash & Current Investments stood at $234.3 million in 2021, then surged by 56.29% to $366.2 million in 2022, then increased by 9.32% to $400.3 million in 2023, then grew by 16.7% to $467.2 million in 2024, then surged by 43.96% to $672.6 million in 2025.
  • Its Cash & Current Investments stands at $672.6 million for Q3 2025, versus $565.3 million for Q2 2025 and $507.0 million for Q1 2025.